Fibrinogen Peptides Inhibit P. acnes Adhesion for Acne Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acne, such as antibiotics and chemical compounds, often have side effects, are costly, and may lead to desensitization or loss of efficacy, necessitating the development of alternative biological means for effective treatment without adverse effects.
Innovation Solution
Identification of a 58-kDa P. acnes surface protein specifically recognized by human fibrinogen, named Pfg, which allows for the development of peptides that inhibit bacterial adhesion to skin cells, using fragments of the human fibrinogen Bβ sub-unit to prevent and treat acne and other inflammatory skin diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics and chemical compounds are used to treat acne, then bacterial growth is inhibited, but side effects and treatment costs increase
Solution Approach 1:
The patent uses fibrinogen peptides as intermediary molecules that block the adhesion between P. acnes bacteria and skin cells. Instead of directly killing bacteria with antibiotics, the peptides act as mediators that prevent bacterial attachment to host cells, thereby reducing inflammation without the harmful side effects of conventional antibiotic treatment
Solution Approach 2:
The invention converts the natural adhesion mechanism of P. acnes bacteria into a beneficial therapeutic effect. By identifying the bacterial adhesion protein Pfg and its binding to fibrinogen, the patent develops peptide fragments that mimic this interaction to prevent pathogenic adhesion, turning understanding of bacterial harmful mechanisms into protective therapeutic agents
2Duration of action of moving object
If antibiotics are used for prolonged periods, then treatment efficacy is maintained, but desensitization and loss of response occur
Solution Approach 1:
The fibrinogen peptides provide a self-sustaining therapeutic mechanism by blocking bacterial adhesion at its initial stage. This prevents the inflammatory cascade before it begins, creating a self-limiting treatment approach that does not lead to bacterial resistance or desensitization issues associated with prolonged antibiotic use
3Reliability
If chemical compounds are used to treat acne, then bacterial adhesion is inhibited, but production cost increases
Solution Approach 1:
The patent segments the large fibrinogen protein into smaller, functional peptide fragments (such as Fg1.1.1 with 10 amino acids) that retain the anti-adhesive activity. This segmentation reduces production complexity and cost while maintaining therapeutic efficacy, as smaller peptides are easier and more economical to manufacture than full-length proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively inhibit P. acnes adhesion to skin cells, reducing inflammation and providing a potential treatment for acne and psoriasis with minimal side effects and lower production costs.
Implementation Method 1
P. acnes can adhere to human skin but also can cause deeper infections by travelling from its seeded area to the site of infection using non specific interactions and then irreversible adhesion process through specific binding
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.